SYNTERA BIORISK
SpeciesSheep, cattle & goatsReleaseNetherlands · 2026-09-07
  1. Global Overview
  2. Europe
  3. Netherlands
  4. Bluetongue
Country–disease dossierNetherlands · Bluetongue
View economic evidence Run scenarioCompare interventionsInspect BCR assumptions Vaccine & intervention marketTrade analysis
Netherlands cross-disease portfolio NETHERLANDS DISEASE PROFILE · LINKED WORKSPACE

Bluetongue

Official evidence, 12-province exposure and transparent national planning economics.

Profile readyEvidence + editable CBA
African swine fevernot present external incursion riskHighly pathogenic avian influenzacurrent 2026 infected holdingsBluetonguerecent epidemic no new 2025 detectionsBovine tuberculosisofficially free with residual import riskFoot-and-mouth diseaseofficially free without vaccinationPeste des petits ruminantsofficially freeNewcastle diseasecompulsory preventive vaccinationClassical swine feverofficially freeSheep pox and goat poxno current domestic event external incursion preparednessLumpy skin diseasefree status under external incursion pressureBovine viral diarrhoeaendemic control transitionJohne’s diseaseendemic quality assurance programmeEpizootic haemorrhagic diseasenotifiable no current domestic event in registered source
Official disease status · 2025-12-31

Bluetongue

The Netherlands lost bluetongue-free status in September 2023; BTV-3 and later BTV-12 circulated, while no new infection was detected in 2025.

Selected geography
Netherlands
Susceptible livestock
4.95m
Evidence nature
Observed / official
Exposure layer

Netherlands · susceptible livestock

PDOK BRK 2026
Exposure is livestock inventory—not inferred prevalence. Regional selection updates supported evidence; the CBA remains explicitly national because regional cost evidence is unavailable.
Validated exposure

Netherlands

cattle3.64m
sheep676.02k
goats628.02k

CBS 80783ENG · 2025 final observations; source grain retained.

Official signal at selected grain
  • new infections detected in 20250 infections
Observed economics · national/source scope
Observed direct loss · national
€164m–€175m · 2007
Published programme cost · source scope
N/A
Monetised trade effect
N/A

Peer-reviewed historical epidemic estimate; not a current loss, programme cost or forecast.

Relevant wildlife & interface

Wildlife evidence

No compatible current national wildlife-population layer is registered.

Population denominators remain unavailable unless explicitly registered; qualitative host evidence is not converted into a count.
ILLUSTRATIVE

Illustrative scenario—country-specific intervention evidence unavailable.

The planning parameters are retained, but the BCR is not estimated in this public profile.

Open Impact CalculatorWhy these assumptions?
Control choices

Default option scenarios

  1. 01Voluntary vaccinationPlanning option retained for explicit activation in Scenario Lab
  2. 02Vector-season surveillancePlanning option retained for explicit activation in Scenario Lab
  3. 03Movement certificationPlanning option retained for explicit activation in Scenario Lab
Trade & movement

Documented consequence

Animal movements can require vaccination, testing and vector-season controls; vaccination remains an owner decision under current Dutch policy.

Registered sources document controls but not a compatible Netherlands-wide monetised consequence.
Evidence register

5 sources used in this view

Release principle: every Netherlands disease has a complete decision workspace. Missing observed economics stay visible as N/A; modelled planning values are separately labelled, editable and never presented as evidence.
Sustainability & One HealthCountry-specific GHG, AMU/AMR and biodiversity results remain withheld until compatible evidence is registered; none is inferred from the disease profile.
Request complete Decision Brief